Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCXNASDAQ:HSAQNYSE:NSPRNASDAQ:OBLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.57-12.0%$1.81$0.17▼$1.99$53.73M0.514.17 million shs52,438 shsHSAQHealth Sciences Acquisitions Co. 2$3.22+3.9%$2.91$9.41▼$13.80$36.10M0.09205,918 shs194,614 shsNSPRInspireMD$2.26+0.9%$2.47$1.99▼$3.80$69.24M0.5964,193 shs254,752 shsOBLNObalon Therapeutics$2.38-3.3%$4.22$0.66▼$10.77$23.85M-1.237.68 million shs1.53 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell-11.99%+13.22%+7.98%+1,558.06%+131.53%HSAQHealth Sciences Acquisitions Co. 20.00%+7.69%+18.38%-27.48%-53.06%NSPRInspireMD+0.89%-6.61%-9.24%-16.30%-9.31%OBLNObalon Therapeutics-6.11%-3.91%-48.32%+458.46%+1,125.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AN/AN/AN/ANSPRInspireMD2.5085 of 5 stars3.52.00.00.02.02.50.6OBLNObalon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AHSAQHealth Sciences Acquisitions Co. 2 0.00N/AN/AN/ANSPRInspireMD 3.00Buy$4.5099.12% UpsideOBLNObalon Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OBLN, NSPR, CTCX, and HSAQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K1,636.04N/AN/A$1.07 per share2.40HSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/A($0.62) per shareN/ANSPRInspireMD$7.03M9.85N/AN/A$1.83 per share1.23OBLNObalon Therapeutics$1.59M15.00N/AN/A$0.60 per share3.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AHSAQHealth Sciences Acquisitions Co. 2-$380KN/A0.00∞N/AN/AN/A-2.38%N/ANSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/AOBLNObalon Therapeutics-$12.33MN/AN/A∞N/A-776.76%-161.38%-83.58%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/AOBLNObalon TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29HSAQHealth Sciences Acquisitions Co. 2N/A0.170.61NSPRInspireMDN/A6.396.05OBLNObalon TherapeuticsN/A1.861.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%HSAQHealth Sciences Acquisitions Co. 289.71%NSPRInspireMD44.78%OBLNObalon Therapeutics18.64%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%HSAQHealth Sciences Acquisitions Co. 221.90%NSPRInspireMD29.72%OBLNObalon Therapeutics8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableHSAQHealth Sciences Acquisitions Co. 2411.21 million8.76 millionNot OptionableNSPRInspireMD5030.64 million18.33 millionOptionableOBLNObalon Therapeutics210.02 millionN/ANot OptionableOBLN, NSPR, CTCX, and HSAQ HeadlinesRecent News About These CompaniesInterWest Management Partners X, LLC's Net WorthAugust 4, 2024 | benzinga.comObalon Therapeutics, Inc.February 25, 2024 | thestreet.comSpero Therapeutics Inc.February 6, 2024 | wsj.comIntragastric Balloon Market Growth and Forecast till 2031March 28, 2023 | marketwatch.comIntragastric Balloons Market to Grow with a Significant CAGR During the forecast period 2022-2028| Exclusive Report Spread Across 149 PagesAugust 17, 2022 | marketwatch.comRenovare Environmental Inc (RENO)January 5, 2022 | investing.comUnderstanding Atara Biotherapeutics's Unusual Options ActivityAugust 10, 2021 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOBLN, NSPR, CTCX, and HSAQ Company DescriptionsCarmell NASDAQ:CTCX$2.57 -0.35 (-11.99%) As of 06/25/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ$3.22 +0.12 (+3.87%) As of 06/24/2025Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.InspireMD NYSE:NSPR$2.26 +0.02 (+0.89%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.17 -0.09 (-3.98%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Obalon Therapeutics NASDAQ:OBLNObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
